BioSpace News Archive

Long-term results from SPIRIT-H2H show robust efficacy of Taltz as monotherapy or in combination with methotrexate or additional csDMARDs

Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced CEO Dr. Pnina Fishman will share insight into the company’s recent developments and upcoming milestones during an investor webinar on Thursday, June 4th, 2020 at 11:00 a.m. ET.

Acerus Announces Significant Improvement in NATESTO ® Insurance Coverage in the United States NATESTO ® now covered as a Preferred Brand by leading national pharmacy benefits manager TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., on

CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico.

First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Covalon Technologies Ltd., an advanced medical technologies company, announced that the Company has been granted key antimicrobial patents by the United States Patent and Trademark Office, the Canadian Intellectual Property Office, and the European Patent Office.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that John Koconis, CEO of Timber, will present a corporate overview of the company, its development pipeline and near-term milestones at the Virtual Sum

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that patient enrollment in its Phase 3 clinical trial evaluating eprenetapopt with azacitidine for the treatment of front-line TP53 mutan

Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at BIO Digital 2020, being held virtually June 8-12, 2020. In addition to completion of its merger with Conatus Pharmaceuticals in May 2020, enrollment is currently underway in Histogen’s Phase 1b/2a clinical trial of its lead product candi